Peer-reviewed veterinary case report
Canine and feline fibrosarcoma treatment with Acemannan and surgery
By King, G K et al.·Published in Journal of the American Animal Hospital Association·1995·Gulf Coast Veterinary Specialists, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The effect of Acemannan Immunostimulant in combination with surgery and radiation therapy on spontaneous canine and feline fibrosarcomas.
Plain-English summary
A group of eight dogs and five cats with confirmed fibrosarcomas (a type of tumor) that had not responded to previous treatments were given a new immunostimulant called Acemannan along with surgery and radiation therapy. After four to seven weeks of Acemannan treatments, some animals showed significant tumor shrinkage, and all underwent surgery to remove the tumors. Following surgery, they received radiation therapy and continued Acemannan treatments monthly for a year. Remarkably, seven of the 13 pets are still alive and free of tumors after more than a year, suggesting that Acemannan may help improve outcomes when combined with traditional treatments.
People also search for: dog fibrosarcoma treatment · cat tumor surgery recovery · Acemannan for pets · radiation therapy for dog cancer · what to expect after cat tumor surgery
Abstract
Eight dogs and five cats with histopathologically confirmed fibrosarcomas were treated with Acemannan Immunostimulanta in combination with surgery and radiation therapy. These animals had recurring disease that had failed previous treatment, a poor prognosis for survival, or both. Following four to seven weekly acemannan treatments, tumor shrinkage occurred in four (greater than 50%; n = 2) of 12 animals, with tumors accessible to measurement. A notable increase in necrosis and inflammation was observed. Complete surgical excision was performed on all animals between the fourth and seventh week following initiation of acemannan therapy. Radiation therapy was instituted immediately after surgery. Acemannan treatments were continued monthly for one year. Seven of the 13 animals remain alive and tumor-free (range, 440+ to 603+ days) with a median survival time of 372 days. The data suggests that Acemannan Immunostimulant may be an effective adjunct to surgery and radiation therapy in the treatment of canine and feline fibrosarcomas.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/8542364/